drugset
drugset / Trial / NCT03080987

A Study to Assess the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of JNJ-64179375 in Healthy Japanese Participants

NCT03080987 ↗

Phase 1 Completed 40 enrolled Janssen Research & Development, LLC
RandomizedParallel-groupDouble-blindTreatment

Summary

The primary purpose of this study is to assess the safety and tolerability of JNJ-64179375 in Part 1 and 2.

Timeline

Start
2017-06-27
Primary completion
2018-06-25
Completion
2018-06-25

Drugs

EvaluationDrugModalityDoseRoute
Subject ICHORCUMAB Monoclonal antibody 0.3 mg/kg Intravenous
Subject ICHORCUMAB Monoclonal antibody 1 mg/kg Intravenous
Subject ICHORCUMAB Monoclonal antibody 2.5 mg/kg Intravenous

Indications

No indication recorded.